- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04438213
Ertugliflozin in Chronic Heart Failure
Ertugliflozin in Chronic Heart Failure: Cardio-renal and Diuretic Effects
The purpose of this study is to determine the effects on heart failure signs and symptoms of the use of either ertugliflozin, metolazone or placebo, in conjunction with intravenous loop diuretic use in acute settings and chronic oral loop diuretic therapy.
There are two general purposes for this study. The proposed study is both larger and more rigorous than essentially all PK/PD studies that form the basis of current practice with loop diuretics as well as all studies looking at add-on thiazide therapy (current guideline-recommended adjuvant). The second is to generate a mechanistic understanding of the pleotropic cardio-renal factors with chronic therapy that differentiate ertugliflozin from traditional diuretics particularly in how they maintain reduced blood volume without the complication of over-diuresis and volume depletion.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Katherine Keith, RN
- Phone Number: (203) 737-3571
- Email: katherine.keith@yale.edu
Study Contact Backup
- Name: Veena Rao, PhD
- Phone Number: (203) 785-7917
- Email: veena.s.rao@yale.edu
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Recruiting
- Yale School of Medicine
-
Principal Investigator:
- Jeffrey Testani, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- A clinical diagnosis of ADHF with at least one objective sign of volume overload (rales, edema, elevated JVP, or preadmission weight gain)
- As judged by the treating physician, a projected need and ability to tolerate treatment with an extended need for IV diuretics with the goal of significant fluid removal (i.e., goal >1L/day net fluid loss)
- Chronic daily oral loop diuretic dose > or equal to 20mg furosemide equivalents for at least one month prior to admission
- eGFR 30 mL/min/1.73 m2
- Signed informed consent
Exclusion Criteria:
- Current use or plan to initiate renal replacement therapy or ultrafiltration this hospital admission
- Significant bladder dysfunction or urinary incontinence
- Inability to comply with the serial urine collection procedures
- Current use of a thiazide or thiazide like diuretics or use within 5 half-lives of the drug, including metolazone
- Prior heart transplant, critical stenotic valvular disease or complex congenital heart
- History of type 1 diabetes, diabetic ketoacidosis, "brittle" diabetes or frequent hypoglycemia or severe hypoglycemic episodes requiring emergent intervention (ER visit or EMS response, glucagon administration or forced oral carbs) in the last 3 months
- History of or current urosepsis or frequent urinary tract infections
- Anemia with hemoglobin <8g/dL (due to required phlebotomy for the study)
- Pregnancy or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ertugliflozin
Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
|
Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
|
Experimental: Metolazone
Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
|
Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
|
Placebo Comparator: Placebo
Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
|
Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Natriuretic effect of adjuvant to loop diuretic therapy
Time Frame: 1 day
|
The natriuretic effect (urine sodium concentration) of each arm with loop diuretic therapy will be measured by the urine sodium output.
|
1 day
|
Change from baseline to day 7 of total body water by add-on to loop diuretic therapy (Chronic)
Time Frame: 7 days
|
The primary outcome of the chronic effects of add-on placebo, thiazide-like diuretic, or SGLT2 inhibitor is to determine the change in total body water from baseline to day 7
|
7 days
|
Change from baseline to 6 weeks total body water by add-on to loop diuretic therapy (Chronic)
Time Frame: 6 weeks
|
The primary outcome of the chronic effects of add-on placebo, thiazide-like diuretic, or SGLT2 inhibitor is to determine the change in total body water from baseline to 6 weeks.
|
6 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Heart Failure
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Natriuretic Agents
- Membrane Transport Modulators
- Diuretics
- Sodium-Glucose Transporter 2 Inhibitors
- Sodium Chloride Symporter Inhibitors
- Ertugliflozin
- Metolazone
Other Study ID Numbers
- 2000027951
- MISP59625 (Other Grant/Funding Number: Merck Sharp & Dohme)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
US Department of Veterans AffairsCompleted
Clinical Trials on Ertugliflozin
-
Merck Sharp & Dohme LLCPfizerActive, not recruitingType 2 Diabetes MellitusUnited States, Belgium, Canada, Colombia, Costa Rica, Dominican Republic, France, Guatemala, Hungary, Israel, Italy, Malaysia, Mauritius, Mexico, Philippines, Poland, Russian Federation, Saudi Arabia, Turkey, Ukraine, United Arab... and more
-
Merck Sharp & Dohme LLCPfizerCompleted
-
Merck Sharp & Dohme LLCPfizerCompleted
-
Merck Sharp & Dohme LLCPfizerCompletedType 2 Diabetes Mellitus
-
Merck Sharp & Dohme LLCPfizerCompleted
-
Merck Sharp & Dohme LLCPfizerCompleted
-
Merck Sharp & Dohme LLCPfizerCompletedType 2 Diabetes Mellitus | Hepatic Impairment
-
Aga Khan UniversityCompletedHypertension | Diabetes Mellitus | Hypercholesterolemia | Metabolic Syndrome XPakistan
-
Merck Sharp & Dohme LLCPfizerCompleted
-
Merck Sharp & Dohme LLCPfizerCompleted